1292PPhase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. (23rd October 2018) - Owonikoko, T K; Papadopoulos, K P; Gil-Martin, M; Moreno, V; Salama, A K; Calvo, E; Safran, H; González-Martín, A; Aljumaily, R; Mahadevan, D; Niu, J; Kal Mohan, K; et al.